← Leaderboards
Robert Floyd Pass
University Of Alabama At Birmingham
$10,874,670
Attributed
$10,874,670
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$14,791,558 · 13
By mechanism
U01$9,549,278 · 2
P01$4,415,992 · 2
M01$826,288 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- William J Britt$28,989,956
- Edward W Hook$14,329,104
- Michael Mach$1,636,063
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusHuman SubjectClinical ResearchHuman Therapy EvaluationVertical TransmissionCongenital InfectionFemaleNeutralizing AntibodyPathologic ProcessHuman Pregnant SubjectGlycoproteinsDisease /Disorder Prevention /ControlClinical TrialsAids TherapyAids Education /PreventionCooperative StudyPlacebosBehavioral /Social Science Research TagPregnancyMother /Infant Health CarePatient Oriented ResearchAids VaccinesEnrollmentHerpesviridae Disease
Grant awards (36)
CMV Subunit Vaccine in Young Women at Risk$46,222
U01 · FY2010 · AI · contact PI
CMV Subunit Vaccine in Young Women at Risk$475,689
U01 · FY2009 · AI · contact PI
CMV Subunit Vaccine in Young Women at Risk$787,173
U01 · FY2008 · AI · contact PI
CMV Subunit Vaccine in Young Women at Risk$935,465
U01 · FY2007 · AI · contact PI
RECOMBINANT CMV GB VACCINE IN POST-PARTUM WOMEN$184,896
M01 · FY2007 · RR · contact PI
PACTG P1026S PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS IN PREGNANCY$7,170
M01 · FY2007 · RR · contact PI
PACTG 1038$895
M01 · FY2007 · RR · contact PI
CMV Subunit Vaccine in Young Women at Risk$973,147
U01 · FY2006 · AI · contact PI
RECOMBINANT CMV GB VACCINE IN POST-PARTUM WOMEN$171,552
M01 · FY2006 · RR · contact PI
PACTG P1026S PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS IN PREGNANCY$1,143
M01 · FY2006 · RR · contact PI
CMV Subunit Vaccine in Young Women at Risk$972,591
U01 · FY2005 · AI
Southeast Pediatric AIDS Clinical Trials Unit$730,908
U01 · FY2005 · AI
RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN$183,371
M01 · FY2005 · RR
OBSERVATIONAL STUDY OF PRIMARY CMV INFECTION IN YOUNG WOMEN$5,246
M01 · FY2005 · RR
PACTG P 1020A VERSION 20 PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY STU$2,765
M01 · FY2005 · RR
Southeast Pediatric AIDS Clinical Trials Unit$706,138
U01 · FY2004 · AI
CMV Subunit Vaccine in Young Women at Risk$484,341
U01 · FY2004 · AI
PREVENTION OF MATERNAL AND CONGENITAL CMV INFECTION$275,372
P01 · FY2004 · AI
Recombinant CMV gB vaccine in post-partum women$230,511
M01 · FY2004 · RR
Southeast Pediatric AIDS Clinical Trials Unit$39,378
U01 · FY2004 · AI
Observational Study of CMV Infection in Young Women$7,472
M01 · FY2004 · RR
PHASE I/II, OPEN-LABEL, PHARMACOKINETIC AND SAFETY$1,738
M01 · FY2004 · RR
Southeast Pediatric AIDS Clinical Trials Unit$723,865
U01 · FY2003 · AI
PREVENTION OF MATERNAL AND CONGENITAL CMV INFECTION$1,173,358
P01 · FY2002 · AI
Southeast Pediatric AIDS Clinical Trials Unit$721,600
U01 · FY2002 · AI
PHASE II/II TRIAL OF RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN$157,141
P01 · FY2002 · AI
NATURAL HISTORY OF CONGENITALLY &NATALLY ACQUIRED CYTOMEGALOVIRUS INFECTION$0
M01 · FY2002 · RR
PREVENTION OF MATERNAL AND CONGENITAL CMV INFECTION$1,378,590
P01 · FY2001 · AI
SOUTHEAST PEDIATRIC AIDS CLINICAL TRIALS UNIT$1,136,202
U01 · FY2001 · AI
PHASE II/II TRIAL OF RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN$157,141
P01 · FY2001 · AI
NATURAL HISTORY OF CONGENITALLY &NATALLY ACQUIRED CYTOMEGALOVIRUS INFECTION$0
M01 · FY2001 · RR
PREVENTION OF MATERNAL AND CONGENITAL CMV INFECTION$1,089,568
P01 · FY2000 · AI
SOUTHEAST PEDIATRIC AIDS CLINICAL TRIALS UNIT$816,559
U01 · FY2000 · AI
PHASE II/II TRIAL OF RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN$184,822
P01 · FY2000 · AI
NATURAL HISTORY OF CONGENITALLY &NATALLY ACQUIRED CYTOMEGALOVIRUS INFECTION$29,529
M01 · FY2000 · RR
TRIAL OF RECOMBINANT CMV GB VACCINE IN POSTPARTUM WOMEN$0
M01 · FY2000 · RR